Ionis Pharmaceuticals - Latest News and Information
IONS
Ionis Pharmaceuticals is a biopharmaceutical company focused on discovering and delivering RNA- and DNA-targeted medicines to address serious diseases. Through antisense chemistry and innovative genetic therapies, the company pursues treatments across neurology, cardiometabolic disorders, and select rare diseases, aiming to improve patient outcomes globally. Headquartered in Carlsbad, California, Ionis combines scientific expertise with a deep pipeline to advance next-generation therapies from research to clinical development.
GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run
Deep Dive: Huntington’s at a Crossroads
Hepatitis B: Are We Edging Closer to a Cure?
EU Approves Otsuka's Long-Acting HAE Drug Dawnzera
Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations
2026 Cardiovascular Catalysts: Lp(a) on the Horizon
2025 Novel Large Molecule FDA Drug Approvals
JPM26: KalVista’s HAE Win Is a ‘Tale of Two Markets’
Patent Losses Hit Novartis Hard, but CEO Has a Plan
Despite Wide Support for Rare Disease, Voucher Program Caught Up in Senate's ICE Fight
Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b
No recent deals for this company.
